Multiple myeloma

Florida Cancer Specialists & Research Institute Best Practices Program Improves Treatment Response and Survival for Patients with Multiple Myeloma

Retrieved on: 
Thursday, January 25, 2024
Real-World Evidence, Death, Incidence, RN, BSN, Bachelor of Pharmacy, Partnership, Survival, RRMM, Multiple myeloma, CAPM, Bone marrow, Data, FDA, Current Oncology, FCS, Doctor of Philosophy, RPH, OCN, BP, Infrared spectroscopy correlation table, Immune system, Nursing

FORT MYERS, Fla., Jan. 25, 2024 /PRNewswire/ -- A best practices program developed at Florida Cancer Specialists & Research Institute (FCS) has been shown to improve outcomes for adult patients prescribed selinexor for the treatment of relapsed/refractory multiple myeloma (RRMM).

Key Points: 
  • A real-world study by FCS authors details a program to improve patient outcomes for multiple myeloma.
  • Results obtained from a one-year retrospective observational study using data collected by FCS' Real-World Evidence team were recently published in Current Oncology.
  • He added, "Our findings, as detailed in this article, support the hypothesis that a best practices program designed around specific anticancer drugs can optimize prescribing practices, leading to better disease control and improvements in a patient's cancer care journey."
  • The FCS Real-World Evidence team works with internal and external partners providing insights to improve treatment decisions and clinical outcomes based on evidence generated using real-world data.

Conversations on Cancer: Transforming Patient Lives by Therapeutic and Regulatory Innovations, European Medicines Agency, Amsterdam, the Netherlands, from 1 February 2024, 15:30 (CET) to 1 February 2024, 17:00 (CET)

Retrieved on: 
Friday, January 19, 2024
Role, Patient, OCE, Accelerated approval (FDA), Melanoma, European Medicines Agency, EMA, Outline, Location, Multiple myeloma, Therapy, Acute leukemia, Pharmaceutical industry

The conversation will focus on the introduction of certain innovative therapeutic classes in the past two decades that have revolutionized the care for patients with chronic myeloid leukemia, multiple myeloma, and melanoma.

Key Points: 
  • The conversation will focus on the introduction of certain innovative therapeutic classes in the past two decades that have revolutionized the care for patients with chronic myeloid leukemia, multiple myeloma, and melanoma.
  • The discussion will provide an overview of regulatory programs that expedite access to patients, including FDA’s Breakthrough therapy designation and Accelerated Approval; and EMA’s Prime and Conditional Approval.
  • The panel of patients, investigators and regulators aims to highlight successes from development to approval.
  • We’ll specifically outline:
    - Patient experiences with new innovative therapeutic classes;
    - Investigator approaches in development;
    - Role of regulatory collaboration and programs to expedite development and approval of novel, safe, and effective therapeutics.

Promega Research Shows Potential of Selective Degrader Against Pediatric Cancer Cell Lines

Retrieved on: 
Tuesday, January 16, 2024
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Hospitals, Clinical Trials, Multimedia, Nature Communications, Cell proliferation, Multiple myeloma, Jude the Apostle

Promega research published today in Nature Communications demonstrates a new potential approach for managing multiple myeloma and other hematological cancers.

Key Points: 
  • Promega research published today in Nature Communications demonstrates a new potential approach for managing multiple myeloma and other hematological cancers.
  • The molecule, called SJ3149, demonstrates potent anti-proliferative activity in a variety of human cancer cell lines through selective degradation of the cancer-causing protein CK1α.
  • They report that SJ3149 potently and selectively degrades CK1α and limits the proliferation of multiple cancer cell lines spanning a wide range of disease subtypes.
  • Their results strongly support future research on applying selective CK1α degraders to many different cancer types.

Avenacy Announces Launch of Melphalan Hydrochloride for Injection in the U.S. Market

Retrieved on: 
Tuesday, January 16, 2024
Biotechnology, General Health, FDA, Health, Pharmaceutical, Entrepreneurship, Patient, Hospital, Temperature, Anaphylaxis, Food, Multiple myeloma, Chromosome, Human, Melphalan, Safety, Bone marrow, Boxed warning, Bleeding, Aplastic anemia, Infection, Abbreviated New Drug Application, Pharmaceutical industry

Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, today announced it has launched Melphalan Hydrochloride for Injection in the United States as a therapeutic equivalent generic for Alkeran® for Injection (melphalan hydrochloride) approved by the U.S. Food and Drug Administration.

Key Points: 
  • Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, today announced it has launched Melphalan Hydrochloride for Injection in the United States as a therapeutic equivalent generic for Alkeran® for Injection (melphalan hydrochloride) approved by the U.S. Food and Drug Administration.
  • Melphalan Hydrochloride for Injection is indicated for the palliative treatment of patients with multiple myeloma for whom oral therapy is not appropriate.
  • Avenacy’s Melphalan Hydrochloride for Injection is available in a kit containing a 50mg vial of lyophilized active ingredient and a 10mL vial of sterile diluent for admixture.
  • “Melphalan Hydrochloride for Injection will feature our proprietary product packaging and labeling, supporting our commitment to championing reliability, safety, and convenience for our customers.

Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 8-11 January 2024

Retrieved on: 
Saturday, January 13, 2024
B cell, Risk management, Association, Data, Patient, Leukemia, European, Signal, Database, Brexucabtagene autoleucel, DSM-IV codes, Father, B-cell lymphoma, Follicular lymphoma, State, Mantle cell lymphoma, Male, RMP, Migraine, Civil service commission, European Commission, Birth, Medicine, Cancer, EMA, Risk, Public, Communication, Bipolar disorder, Pregnancy, T-cell lymphoma, Multiple myeloma, Epilepsy, COVID-19, Child, PRAC, Bone marrow, Neurodevelopmental disorder, Marketing, B-cell leukemia, Vaccine, Review, Man

EMA’s safety committee (PRAC) is recommending precautionary measures for the treatment of male patients with valproate medicines.

Key Points: 
  • EMA’s safety committee (PRAC) is recommending precautionary measures for the treatment of male patients with valproate medicines.
  • A safety signal is information which suggests a new potentially causal association, or a new aspect of a known association between a medicine…, Ongoing referralsProcedureStatusUpdateHydroxyprogesterone-containing medicinal products – Article-31 referralUnder evaluationPRAC continued its assessment

International Myeloma Foundation and the Black Swan Research Initiative Showcase Six Oral & Poster Abstracts by the iStopMM Project at the 2023 ASH Annual Meeting

Retrieved on: 
Friday, January 12, 2024
Projection screen, MGUS, Risk, Research, Body mass index, Multiple myeloma, Smoking, IMF, Thrombosis, BSRI, SMM, Sense, Conference, Abstract, ASH, Treatment, Abstract (summary), Cosmetics

( Abstract #3397: Risk Factors of Smoldering Multiple Myeloma: Results from the Screened iStopMM Study )

Key Points: 
  • ( Abstract #3397: Risk Factors of Smoldering Multiple Myeloma: Results from the Screened iStopMM Study )
    A Media Snippet accompanying this announcement is available by clicking on this link.
  • In a recent Ask Dr. Durie video , IMF Chairman of the Board and Chief Scientific Officer Dr. Brian G.M.
  • Durie discusses the iStopMM Project’s purpose in doing the large-scale screening study and the advantages that come with early screening.
  • You may also access the complete list of 2023 ASH Abstract Achievement Awardees on the ASH website.

C4 Therapeutics Announces 2024 Priorities and Extended Cash Runway to Advance Portfolio of Targeted Protein Degradation Medicines

Retrieved on: 
Tuesday, January 9, 2024
International Myeloma Foundation, Patient, PST, Therapy, Research, Conjugation, Melanoma, ATM, Biogen, Cancer, Drug discovery, PD, CCCC, Security, Multiple myeloma, DAC, Conference, Lung cancer, Webcast, Investigational New Drug, Workforce, Merck, BRAF, Colorectal cancer, Roche, EST, BCMA, Pharmaceutical industry

WATERTOWN, Mass., Jan. 09, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced 2024 priorities to execute against its strategic plan to leverage the benefits of targeted protein degradation across drug discovery and clinical development to create and deliver breakthrough therapies for patients. These priorities capitalize upon recent clinical data and key decisions, resulting in a sharpened focus on executing high-potential programs to ensure achievement of near-term milestones that position C4T for future success.

Key Points: 
  • As a result of this prioritized portfolio, C4T is restructuring its operations and reducing its workforce by approximately 30%.
  • C4T has strengthened its balance sheet to ensure sufficient runway to execute through and beyond critical value-inflecting clinical and discovery milestones.
  • “Building on recent momentum, we are well positioned to make meaningful advances across our portfolio in 2024.
  • Unaudited cash, cash equivalents and marketable securities as of January 5, 2024 were approximately $330 million.

Indapta Therapeutics Announces First Patients Treated with IDP-023 Allogeneic Natural Killer (NK) Cell Therapy for Cancer

Retrieved on: 
Thursday, January 11, 2024
Oncology, Health, Hospitals, General Health, Clinical Trials, Pharmaceutical, Biotechnology, NK, Patient, Therapy, CMV, Cytokine, University, Cancer, Interleukin, GMP, Lymphoma, Multiple myeloma, Safety, Cytomegalovirus, Daratumumab, MD Anderson Cancer Center, Cell, Vaccine

Indapta Therapeutics, Inc., a privately held biotechnology company developing IDP-023, a natural killer (NK) cell therapy for the treatment of cancer, today announced that the company has initiated treatment of the first patients in its Phase 1 trial in multiple myeloma and Non-Hodgkin’s lymphoma.

Key Points: 
  • Indapta Therapeutics, Inc., a privately held biotechnology company developing IDP-023, a natural killer (NK) cell therapy for the treatment of cancer, today announced that the company has initiated treatment of the first patients in its Phase 1 trial in multiple myeloma and Non-Hodgkin’s lymphoma.
  • The patients were treated at the University of Texas MD Anderson Cancer Center and NEXT Oncology, Virginia.
  • To generate IDP-023, Indapta preferentially expands g-NK cells from healthy donors with increased numbers of g-NK cells.
  • Indapta’s off-the-shelf g-NK cell therapy is further differentiated from other NK cell therapies in that it is a cryopreserved product with low variability.

Precision BioSciences Completes License Deal with TG Therapeutics for Cell Therapy Azer-Cel in Treatment of Autoimmune Diseases

Retrieved on: 
Tuesday, January 9, 2024
Research, Infectious Diseases, Genetics, Clinical Trials, Biotechnology, Health, Pharmaceutical, Science, Oncology, Patient, Therapy, PMM, ATM, Precision, Precision BioSciences, VWAP, Imugene, Cancer, Economics, Optimism, Multiple myeloma, HBV, Immunology, Gene editing, BCMA, Vaccine

“We are excited to extend the utility of our allogeneic CAR T assets into immunology by collaborating with TG Therapeutics as they advance novel treatments for B-cell diseases.

Key Points: 
  • “We are excited to extend the utility of our allogeneic CAR T assets into immunology by collaborating with TG Therapeutics as they advance novel treatments for B-cell diseases.
  • Precision will also receive $2.5 million within 12 months, as an equity investment in Precision’s common stock at 100% premium to the then 30-day VWAP prior to purchase.
  • Upon the achievement of certain near-term clinical milestones, Precision will receive an additional $7.5 million payment in cash and the purchase of Precision common stock by TG Therapeutics at a 100% premium to the then current 30-day VWAP.
  • These transactions are expected to extend our runway and will fund continued development of our wholly owned in vivo gene editing programs.

San Francisco Witnesses the Voice of GCT Titans GenScript Biotech Global Forum Outlines the Future of the Industry

Retrieved on: 
Friday, January 12, 2024
Stanford University, DSM-IV codes, Overalls, Gene therapy, Flagship Pioneering, Biotechnology, Artificial intelligence, Neogene, CBER, Gene editing, Genome editing, Assistant professor, Therapy, Biological engineering, SAN, Humour, Harvard University, GenScript Biotech, Optimism, Safety, Patient, J. P. Morgan, AstraZeneca, Hope, GCT, Broad Institute, CBO, Process, Animal, Gene, ARCH Venture Partners, Multiple myeloma, Speech, Intellia Therapeutics, Development, Associate, Health, CRISPR, Intelligence, Courage, Research and development, Division, Conference, T cell, FDA, Eli Lilly and Company, SVP, Pharmaceutical industry

On January 10 this year, GenScript Biotech hosted the "Satellite Session" of the J.P. Morgan annual conference—the 2024 GenScript Biotech Global Forum in San Francisco.

Key Points: 
  • On January 10 this year, GenScript Biotech hosted the "Satellite Session" of the J.P. Morgan annual conference—the 2024 GenScript Biotech Global Forum in San Francisco.
  • GenScript Biotech is committed to building a high-quality platform for exchange and cooperation for global peers, driving the advancement of the cell and gene industry.
  • since the first global forum was held in 2020, GenScript Biotech has created numerous valuable opportunities for industry peers.
  • This grand event brought together the wisdom and strength of global elites in the biopharmaceutical industry, sparking a profound discourse on the future of GCT.